Trinity Life Sciences Breaks Down the Barriers for Biopharmaceutical Companies to Gain Actionable Real-World Evidence
Trinity EvidenceFirst Transforms the Time to Accessible Patient Level Insights
Trinity Life Sciences, a leader in global life sciences solutions, introduces Trinity EvidenceFirst, a high-value subscription service that allows biopharmaceutical companies to take advantage of real-world insights like never before. EvidenceFirst allows organizations to benefit from big, robust data without dealing with the complexities, resource requirements, and costs associated with large data sets. With EvidenceFirst, biopharmaceutical companies can now utilize real-world insights on a broader range of projects with faster turnaround times.
Recommended AI News: New Research: Compensation Trends Amid COVID-19
The combination of access to claims data, rigorous methodology, and expert interpretation of results makes EvidenceFirst the first of its kind. Timely insights allow biopharma companies to improve patient outcomes and drive commercial success. Within a week, EvidenceFirst can help HEOR and commercial teams answer four critical questions for a specific indication:
- Who are the patients?
- Where do I find them?
- How are they treated?
- What are their outcomes?
The answers to these questions are presented with consistent reporting that provides actionable insights. Not just a data pull, EvidenceFirst includes the “so what” provided by Trinity’s experts in a dependable format ready to be shared with internal business partners.
“Trinity EvidenceFirst allows pharmaceutical companies, for the first time, to get an early, foundational read on a market quickly, empowering them to identify risks and opportunities sooner,” said Dave Fitzhenry, CEO, Trinity. “The ability to bring timely, high-value, real-world insights to any point in the drug lifecycle is paramount to product and company success.”
EvidenceFirst is Fast, Convenient and Consistent
EvidenceFirst allows pharma companies to gain timely insights from data sources that they might not already have access to or struggle to gain in data sources they already own. The outputs and reporting are provided within a week and always consistent. Providing a predictable consistent set of foundational outputs is critical in building confidence among key internal stakeholders. This also arms biopharma leaders with a way to consistently compare across different populations.
Recommended AI News: HondaJet Elite Delivered to Red Bull Formula 1 Racing Team Scuderia AlphaTauri